By TAmiRNA GmbH
To get in touch with TAmiRNA partners with Biomedica to open up international markets, simply fill out the form below.
Subscribe to Supplier
TAmiRNA partners with Biomedica to open up international markets
Vienna, Austria: – Innovative biotech company TAmiRNA has signed an exclusive agreement with the Austrian-based Biomedica Gruppe conferring worldwide distribution rights to TAmiRNA´s osteomiR™ test and CRO services.
Biomedica is a globally-acting distribution company and a provider of a unique portfolio of proprietary high quality biomarker ELISAs for clinical research of cardiovascular diseases, bone metabolism, and nephrology.
With immediate effect, Biomedica will globally distribute TAmiRNA´s osteomiR™ test kit, which is an innovative, minimally invasive test for bone-quality and fracture-risk assessment using circulating microRNAs, obtained from a simple blood specimen sample. In addition, Biomedica will increase the reach of TAmiRNA’s CRO services for customized microRNA biomarker development.
Biomarker kits and CRO services
Together, Biomedica and TAmiRNA aim to increase the reach of sales and distribution of the osteomiR™ kit and CRO services across Central and Eastern European (CEE) and Switzerland, where Biomedica has established a strong sales network through its local subsidiaries.
The partnership with Biomedica will give TAmiRNA the opportunity to extend their reach into the US market and worldwide using Biomedica’s distribution platform for their biomarker assays.
“This partnership with Biomedica is especially relevant for countries where TAmiRNA has not yet been active, such as those in Central and Eastern Europe,” commented TAmiRNA CEO, Dr. Matthias Hackl.
“This will make our advanced biomarker tools available to researchers working for biotech and pharma companies participating in clinical studies, universities, clinical research groups, potential customers and partners all over the world,” said Dr. Hackl.
This is the second significant alliance that TAmiRNA has reached this year. In February 2017, the company announced it would partner with Swiss-based in silico biomarker and bioinformatics specialist SimplicityBio to create compelling new biomarker development services for clients from academia and biotech industry.
Privately owned and headquartered in Vienna, TAmiRNA GmbH is a biotech company specialized in the identification and validation of non-coding RNAs as biomarkers for age-related diseases. The mission of TAmiRNA is to provide clinically useful biomarkers to improve and prolong patient stability, health and quality of life with increasing age.
TAmiRNA specializes in technologies for profiling levels of circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimally invasive diagnostic tests for early diagnosis and prognosis of disease, or as companion diagnostic tests to support treatment decisions.
TAmiRNA’s pipeline includes developments in osteoporosis, cardiovascular disease, liver disease and cancer developing ‘microRNA kit’ solutions that enable users to quantify the levels of specific microRNA combinations in serum, plasma, urine or other biofluids. The company initially developed kits for bone disease (osteomiR™) and cardiovascular disease (thrombomiRs™).
TAmiRNA also offers contract research services for companies in need of targeted biomarker development. Customers include biopharma companies with drug development programs in human and veterinary medicine, medtech companies and clinical research groups.
TAmiRNA was founded in November 2013 with funding boosted by investigator awards from the American Society for Bone and Mineral Research (ASBMR) and the European Calcified Tissue Society (ECTS).
More information available at: www.tamirna.com
About Biomedica Gruppe
With its headquarters in Vienna (Austria), Biomedica has 11 subsidiaries in Central and Eastern Europe (CEE), employing a team of 250 professionals. Biomedica is a distributor of medical devices, in vitro diagnostics, products for life sciences, and clinical IT for more than 35 years. Additionally, Biomedica provides internationally recognized, high quality ELISAs for clinical research of cardiovascular diseases, bone metabolism, and nephrology.
More information available at: www.bmgrp.com/home/